# Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older

> **NCT04648241** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 165 (actual)

## Conditions studied

- Tick-Borne Encephalitis

## Interventions

- **BIOLOGICAL:** TBE vaccine 0.5 mL
- **BIOLOGICAL:** TBE vaccine 0.25 mL

## Key facts

- **NCT ID:** NCT04648241
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-18
- **Primary completion:** 2022-02-21
- **Final completion:** 2022-02-21
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04648241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04648241, "Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04648241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*